ILAR algorithm applied to the CARRA-JPsA cohort. Data are n (%) unless otherwise indicated.
| Variables | CARRA-JPsA Cohort | p* | |
|---|---|---|---|
| ILAR-negative, 105 Patients | ILAR-positive, 256 Patients | ||
| Subject age at enrollment, yrs, mean ± SD | 12.25 ± 4.20 | 13.21 ± 4.04 | 0.044 |
| Subject age at onset of symptoms, yrs, mean ± SD | 7.61 ± 4.49 | 8.52 ± 4.62 | NS |
| Subject age first rheumatologist, yrs, mean ± SD | 8.64 ± 4.34 | 9.66 ± 4.60 | 0.06 |
| Ethnicity: not Hispanic or Latino | 91 (86.7) | 240 (93.8) | 0.027 |
| Race: white | 98 (93.3) | 241 (94.1) | NS |
| Sex: male | 42 (40.0) | 95 (37.1) | NS |
| Family history of psoriasis | 31 (29.5) | 82 (32.0) | NS |
| HRQOL, mean ± SD, median (range) | 2.18 ± 0.88, 2 (1–4) | 2.16 ± 0.83, 2 (1–5) | NS |
| Parent/subject overall well-being score, mean ± SD, median (range) | 2.17 ± 2.23, 1 (0–9) | 2.40 ± 2.19, 2 (0–9) | NS |
| Parent/subject pain scale score, mean ± SD, median (range) | 2.69 ± 3.02, 2 (0–10) | 2.54 ± 2.47, 2 (0–10) | NS |
| CHAQ score, mean ± SD, median (range) | 0.42 ± 0.56, 0.13 (0–2.63) | 0.31 ± 0.44, 0.13 (0–2.63) | NS |
| PGA, mean ± SD, median (range) | 1.79 ± 1.88, 1 (0–8) | 1.38 ± 1.63, 1 (0–8) | NS |
| Oligoarthritis ever | 52 (51) | 108 (42.2) | NS |
| Polyarthritis ever | 50 (49.0) | 148 (57.8) | NS |
| No. currently active joints, mean ± SD, median (range) | 2.09 ± 4.20, 1 (0–32) | 1.58 ± 2.58, 0 (0–12) | NS |
| Nail pitting ever | 22 (23.4) | 106 (42.9) | 0.001 |
| Dactylitis | 20 (20.6) | 82 (33.2) | 0.022 |
| Psoriasis ever | 10 (10.7) | 223 (87.5) | 0.0001 |
| Enthesitis ever | 37 (38.9) | 75 (30.3) | NS |
| Sacroiliac joint tenderness ever | 14 (14.9) | 43 (17.3) | NS |
| IBD | 1 (1.1) | 4 (1.6) | NS |
| Uveitis | 17 (17.3) | 22 (8.8) | 0.023 |
| ACPA | 5 (11.9) | 2 (2.1) | 0.029 |
| RF | 3 (2.9) | 14 (5.5) | NS |
| ANA | 38 (36.2) | 97 (37.9) | NS |
| HLA-B27–positive | 14 (19.2) | 12 (6.9) | 0.004 |
| Imaging evidence of joint damage | 27 (30.3) | 47 (22.2) | NS |
| Imaging evidence of active sacroiliitis | 3 (30) | 5 (18.5) | NS |
↵* Specific values for p ≤ 0.05 are reported; p value ≤ 0.007 after adjustment for multiple comparisons between patients in the JPsA cohort who fulfill ILAR criteria (ILAR-positive) and those who do not (ILAR-negative). ILAR: International League of Associations for Rheumatology; CARRA: Childhood Arthritis and Rheumatology Research Alliance; JPsA: juvenile psoriatic arthritis; RF: rheumatoid factor; HRQOL: health-related quality of life; CHAQ: Childhood Health Assessment Questionnaire; PGA: physician’s global assessment; NS: nonsignificant; IBD: inflammatory bowel disease; ACPA: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor; ANA: antinuclear antibody test.